IN2014DN05912A - - Google Patents
Info
- Publication number
- IN2014DN05912A IN2014DN05912A IN5912DEN2014A IN2014DN05912A IN 2014DN05912 A IN2014DN05912 A IN 2014DN05912A IN 5912DEN2014 A IN5912DEN2014 A IN 5912DEN2014A IN 2014DN05912 A IN2014DN05912 A IN 2014DN05912A
- Authority
- IN
- India
- Prior art keywords
- aminoamidine polymers
- aminoamidine
- polymers
- preparing
- polynucleotides
- Prior art date
Links
- ZRALSGWEFCBTJO-UHFFFAOYSA-N anhydrous guanidine Natural products NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 abstract 7
- 229920000642 polymer Polymers 0.000 abstract 7
- 238000012377 drug delivery Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 239000007858 starting material Substances 0.000 abstract 2
- 239000000654 additive Substances 0.000 abstract 1
- 150000001299 aldehydes Chemical class 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 150000002527 isonitriles Chemical class 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000000693 micelle Substances 0.000 abstract 1
- 239000011859 microparticle Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000004033 plastic Substances 0.000 abstract 1
- 229920003023 plastic Polymers 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G12/00—Condensation polymers of aldehydes or ketones with only compounds containing hydrogen attached to nitrogen
- C08G12/02—Condensation polymers of aldehydes or ketones with only compounds containing hydrogen attached to nitrogen of aldehydes
- C08G12/04—Condensation polymers of aldehydes or ketones with only compounds containing hydrogen attached to nitrogen of aldehydes with acyclic or carbocyclic compounds
- C08G12/06—Amines
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G12/00—Condensation polymers of aldehydes or ketones with only compounds containing hydrogen attached to nitrogen
- C08G12/02—Condensation polymers of aldehydes or ketones with only compounds containing hydrogen attached to nitrogen of aldehydes
- C08G12/26—Condensation polymers of aldehydes or ketones with only compounds containing hydrogen attached to nitrogen of aldehydes with heterocyclic compounds
- C08G12/34—Condensation polymers of aldehydes or ketones with only compounds containing hydrogen attached to nitrogen of aldehydes with heterocyclic compounds and acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L79/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen or carbon only, not provided for in groups C08L61/00 - C08L77/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161576899P | 2011-12-16 | 2011-12-16 | |
PCT/US2012/069961 WO2013090861A1 (en) | 2011-12-16 | 2012-12-15 | Alpha-aminoamidine polymers and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN05912A true IN2014DN05912A (zh) | 2015-06-05 |
Family
ID=47501483
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN5912DEN2014 IN2014DN05912A (zh) | 2011-12-16 | 2012-12-15 |
Country Status (9)
Country | Link |
---|---|
US (1) | US9872911B2 (zh) |
EP (1) | EP2791210A1 (zh) |
CN (1) | CN104245794A (zh) |
AU (1) | AU2012351967A1 (zh) |
BR (1) | BR112014014599A2 (zh) |
CA (1) | CA2859205A1 (zh) |
EA (1) | EA201491185A1 (zh) |
IN (1) | IN2014DN05912A (zh) |
WO (1) | WO2013090861A1 (zh) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1583562T1 (sl) | 2003-01-06 | 2011-10-28 | Angiochem Inc | AngioPep-1, sorodne spojine in njihove uporabe |
US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
JP2012505637A (ja) | 2008-10-15 | 2012-03-08 | アンジオケム,インコーポレーテッド | Glp−1アゴニストのコンジュゲート及びその使用 |
BRPI0920121A2 (pt) | 2008-10-15 | 2019-09-24 | Angiochem Inc | conjugados de etoposida e doxorubicina para liberação de fármaco |
JP5759379B2 (ja) | 2008-12-05 | 2015-08-05 | アンジオケム インコーポレーテッド | ニューロテンシンまたはニューロテンシンアナログおよびその使用 |
EP2373789A4 (en) | 2008-12-17 | 2012-08-29 | Angiochem Inc | MEMBRANTYP-1 MATRIX METALLOPROTEINASE INHIBITORS AND THEIR USE |
WO2010121379A1 (en) | 2009-04-20 | 2010-10-28 | Angiochem Inc | Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog |
AU2010268726A1 (en) | 2009-07-02 | 2012-01-19 | Angiochem Inc. | Multimeric peptide conjugates and uses thereof |
EP2600901B1 (en) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
ES2737960T3 (es) | 2010-10-01 | 2020-01-17 | Modernatx Inc | Nucleósidos, nucleótidos y ácidos nucleicos modificados y sus usos |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP3682905B1 (en) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
EP2791160B1 (en) | 2011-12-16 | 2022-03-02 | ModernaTX, Inc. | Modified mrna compositions |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
EP4074834A1 (en) | 2012-11-26 | 2022-10-19 | ModernaTX, Inc. | Terminally modified rna |
US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
US20160194625A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
CA2926218A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
CA2951707A1 (en) | 2014-06-10 | 2015-12-17 | Massachusetts Institute Of Technology | Method for gene editing |
CA2955250A1 (en) | 2014-07-16 | 2016-01-21 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
EP3171895A1 (en) | 2014-07-23 | 2017-05-31 | Modernatx, Inc. | Modified polynucleotides for the production of intrabodies |
CA2989400A1 (en) | 2015-06-15 | 2016-12-22 | Angiochem Inc. | Ang1005 for the treatment of leptomeningeal carcinomatosis |
BR112021003897A2 (pt) | 2018-08-30 | 2021-05-25 | Tenaya Therapeutics, Inc. | reprogramação de células cardíacas com miocarina e asci1 |
CA3113353A1 (en) * | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
EP3997226A1 (en) | 2019-07-11 | 2022-05-18 | Tenaya Therapeutics, Inc. | Cardiac cell reprogramming with micrornas and other factors |
US11773391B2 (en) | 2020-04-01 | 2023-10-03 | University of Pittsburgh—of the Commonwealth System of Higher Education | Therapeutic and diagnostic target for SARS-CoV-2 and COVID-19 |
CN112876677B (zh) * | 2020-12-29 | 2022-05-06 | 浙江大学杭州国际科创中心 | 一种多巴胺功能化聚(β-氨基酯)及其制备方法和应用 |
CN114315889B (zh) * | 2021-12-20 | 2024-03-22 | 广东万木新材料科技有限公司 | 一种双官能有机二硅醚类化合物及其合成方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5155174A (en) | 1989-05-08 | 1992-10-13 | American Cyanamid Company | Surface-modified polyacrylonitrile fibrous substrates |
US5922304A (en) | 1989-12-22 | 1999-07-13 | Imarx Pharmaceutical Corp. | Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents |
US6537246B1 (en) | 1997-06-18 | 2003-03-25 | Imarx Therapeutics, Inc. | Oxygen delivery agents and uses for the same |
US7091192B1 (en) | 1998-07-01 | 2006-08-15 | California Institute Of Technology | Linear cyclodextrin copolymers |
US7375096B1 (en) | 1998-12-04 | 2008-05-20 | California Institute Of Technology | Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network |
SE519326C2 (sv) | 1999-11-22 | 2003-02-11 | Astrazeneca Ab | Funktionaliserade polymera reagens innefattande en syralabil isonitrildel samt förfarande för dess framställning |
US7427394B2 (en) | 2000-10-10 | 2008-09-23 | Massachusetts Institute Of Technology | Biodegradable poly(β-amino esters) and uses thereof |
EP2386637B1 (en) | 2001-09-28 | 2018-05-16 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Microrna molecules |
US20030211139A1 (en) * | 2002-05-07 | 2003-11-13 | Thierry Legon | Dispersions of lipid particles for use as therapeutic and cosmetic agents and intracellular delivery vehicles |
TW200640493A (en) | 2005-02-16 | 2006-12-01 | Insert Therapeutics Inc | Cyclodextrin-based polymers for therapeutics delivery |
EP2476756A1 (en) | 2005-06-15 | 2012-07-18 | Massachusetts Institute of Technology | Amine-containing lipids and uses thereof |
US8808681B2 (en) | 2006-06-05 | 2014-08-19 | Massachusetts Institute Of Technology | Crosslinked, degradable polymers and uses thereof |
US8071082B2 (en) | 2006-07-21 | 2011-12-06 | Massachusetts Institute Of Technology | End-modified poly(beta-amino esters) and uses thereof |
JP2010516625A (ja) | 2007-01-24 | 2010-05-20 | インサート セラピューティクス, インコーポレイテッド | 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート |
US20090191244A1 (en) | 2007-09-27 | 2009-07-30 | Children's Medical Center Corporation | Microbubbles and methods for oxygen delivery |
MX2011004859A (es) | 2008-11-07 | 2011-08-03 | Massachusetts Inst Technology | Lipidoides de aminoalcohol y usos de los mismos. |
-
2012
- 2012-12-15 US US14/364,028 patent/US9872911B2/en active Active
- 2012-12-15 AU AU2012351967A patent/AU2012351967A1/en not_active Abandoned
- 2012-12-15 BR BR112014014599A patent/BR112014014599A2/pt not_active IP Right Cessation
- 2012-12-15 EA EA201491185A patent/EA201491185A1/ru unknown
- 2012-12-15 CA CA2859205A patent/CA2859205A1/en not_active Abandoned
- 2012-12-15 IN IN5912DEN2014 patent/IN2014DN05912A/en unknown
- 2012-12-15 CN CN201280069821.XA patent/CN104245794A/zh active Pending
- 2012-12-15 EP EP12809954.6A patent/EP2791210A1/en not_active Withdrawn
- 2012-12-15 WO PCT/US2012/069961 patent/WO2013090861A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
US9872911B2 (en) | 2018-01-23 |
US20140322309A1 (en) | 2014-10-30 |
CA2859205A1 (en) | 2013-06-20 |
EP2791210A1 (en) | 2014-10-22 |
EA201491185A1 (ru) | 2015-05-29 |
AU2012351967A1 (en) | 2014-07-17 |
BR112014014599A2 (pt) | 2017-06-13 |
CN104245794A (zh) | 2014-12-24 |
WO2013090861A1 (en) | 2013-06-20 |
WO2013090861A8 (en) | 2013-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014DN05912A (zh) | ||
MX2021001144A (es) | Lipidoides de aminoalcohol y usos de los mismos. | |
EP4331667A3 (en) | Compositions comprising a delivery agent and preparation thereof | |
IN2014DN00101A (zh) | ||
WO2017044894A3 (en) | Cartilage-homing peptides | |
MX362432B (es) | Variantes de oxm pegilada. | |
MD4575C1 (ro) | Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin | |
WO2012071517A3 (en) | Novel crystalline forms | |
JP2017533218A5 (zh) | ||
MX2013007537A (es) | Formulacion farmaceutica que comprende una droga biofarmaceutica. | |
MX358716B (es) | Composiciones estables para el cuidado bucal que comprenden un aminoácido básico , una sal de estroncio y una fuente de ion fluoruro y usos de las mismas. | |
GEP20186880B (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
MX2017002967A (es) | Composicion farmaceutica novedosa que contiene derivado de acido hidroxamico o sal del mismo. | |
ATE530188T1 (de) | Zusammensetzungen und verfahren zur abgabe von mitteln gegen krebs | |
IN2014MN02248A (zh) | ||
EP2666773A8 (en) | Organic amine salts of azilsartan, preparation method and use thereof | |
MX2022003939A (es) | Composicion farmaceutica de estabilidad mejorada. | |
GB201002413D0 (en) | Nucleic acid complexes | |
MX2012009224A (es) | Compuestos en calidad de antagonistas de bradiquinina-b1. | |
UA117490C2 (uk) | Сполуки ізоіндоліну або ізохіноліну, спосіб їх одержання і фармацевтичні композиції, що їх містять | |
MX341642B (es) | Composicion de liberacion sostenida que contiene peptidos como ingredientes activos. | |
PH12014502407B1 (en) | New alfentanil composition for the treatment of acute pain | |
IL220708A (en) | Compounds whose molecule contains groups 2 - (phenyl / heteroaryl) - [3,1] oxazolo [4,5– d] pyrimidine and carboxy - (heterocyclic nitrogen) carbonyl, also a process for their preparation and pharmaceutical preparations containing them | |
EP4079298A4 (en) | KIT FOR PRODUCING A NANOPARTICLE COMPOSITION FOR ACTIVE DELIVERY WITH POLYLACTIC ACID SALT | |
AU2013338098A8 (en) | Solid salt form of alpha-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof |